

Do You Know or Have a Child or Teenager with Fragile X Syndrome (FXS)?

NOW ENROLLING

**A clinical trial in boys and
girls with FXS ages 3 through 17***



Currently, there are no approved treatments specifically for FXS. We are trying to change that and are now enrolling in a new study called the CONNECT-FX study. An investigational drug called ZYN002 is being studied to determine if it can help manage some of the most common behavioral symptoms associated with FXS.

ABOUT THE STUDY

- ZYN002 is a gel which is applied to the skin twice a day.
- Study related medical exams, study medication and reimbursement of reasonable study-related costs, such as travel and incidental expenses, will be supplied to qualified participants at no cost.
- Participants who complete this study may have an opportunity to enroll in a 1 year follow-on study, where everyone will receive ZYN002, study related medical exams and reimbursement of reasonable study related travel.

TO LEARN MORE, PLEASE CONTACT

Elizabeth DuBose, MPH

(919) 962-5500

elizabeth_dubose@med.unc.edu

*Additional criteria apply

RECRUITMENT SERVICES
PROVIDED IN PART BY THE
NATIONAL FRAGILE X FOUNDATION

SPONSOR


Zynerba[®]
PHARMACEUTICALS
Advancing Science | Improving Connections